Eli Lilly’s Retatrutide Shows Promising Weight Loss in Clinical Trials

Dayton, OH, September 30, 2026 — Eli Lilly’s experimental drug, Retatrutide, has shown substantial weight loss results in recent clinical trials, according to findings published in the peer-reviewed journals The Lancet and the New Jersey Journal of Medicine. The drug, which targets three key metabolic hormones, demonstrated a higher degree of weight reduction compared to currently available medications.

In clinical studies, Retatrutide was observed to help individuals achieve up to a 23% reduction in body weight among participants with Type 2 diabetes. For individuals without Type 2 diabetes, the drug showed an even greater effect, with weight loss reaching up to 30% in some participants.

Retatrutide functions as a triple agonist, meaning it acts on three distinct hormone pathways simultaneously: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon. This multi-target mechanism is designed to enhance metabolic regulation and promote significant weight loss.

The developer, Eli Lilly, has indicated plans to submit Retatrutide to the U.S. Food and Drug Administration (FDA) for approval consideration in the coming year. The specific timeline for this submission was not detailed.

The published studies detailing these outcomes appeared in The Lancet and the New Jersey Journal of Medicine, providing scientific validation for the drug’s reported efficacy in clinical settings. Further details regarding the exact patient populations studied, the duration of the trials, and the specific methodologies employed were presented in these publications.

Story summarized from the original created by Natalie Dreier, Cox Media Group National Content Desk on www.whio.com, see more information here.

Media gallery